Q-omics provides the consensus-scored EDIL3-DT profile across patient tissues and cancer cell-line models. EDIL3-DT expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, EDIL3-DT is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, EDIL3-DT RNA expression shows 14,518 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, KIRP, and PDAC as cancer lineages where EDIL3-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EDIL3-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EDIL3-DT survival associations across molecular data types. EDIL3-DT RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EDIL3-DT RNA expression–survival associations across cancer types. High EDIL3-DT expression shows unfavorable associations in MESO, STAD, ACC and UVM, but favorable associations in KIRP and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for EDIL3-DT RNA expression.
This table summarizes EDIL3-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for EDIL3-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EDIL3-DT shows lower tumor expression in COAD and KICH and higher tumor expression in KIRP, KIRC, HNSC and LIHC. The KIRP box plot shows higher EDIL3-DT RNA expression in tumor versus normal tissue (log2 FC = +2.276, t-test p < 0.001).
This table shows molecular features associated with EDIL3-DT in patient tissues and cancer cell lines. In patient samples, EDIL3-DT shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
